NCT00867139

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Fred Hutchinson Cancer Center · Academic / Other
• Sex: All
• Age: 1 Year
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD

Conditions

• Influenza

Interventions

Type	Name	Description
DRUG	TCAD	TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
DRUG	Zanamivir or Oseltamivir	Zanamivir or Oseltamivir
OTHER	Open label treatment with TCAD	TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-08-01
• Completion: 2010-01-01
• First posted: 2009-03-23
• Last updated: 2013-08-15
• Results posted: 2013-06-04

Locations

2 sites across 1 country: United States